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We examined the potential interac-
tions of anatomic site (head and arms
versus trunk and legs) and CSD (CSD
versus non-CSD melanoma) as proxy
measures of sun exposure on the
relationship between MC1R status (any
variant) and BRAF-mutant melanoma.
No statistically significant interactions
were found (data not shown).
In a study by Landi et al. (2006),
D84E, R142H, and c.86_87insA were
defined as ‘‘r’’ rather than ‘‘R’’. Reclassi-
fication of these variants as ‘‘r’’ did not
significantly change the results (data not
shown). For purposes of comparison with
cases included by Landi et al. and
Fargnoli et al., we repeated all analyses
excluding two cases with melanomas on
acral skin and four cases with positive or
indeterminate germline CDKN2A muta-
tions (Orlow et al., 2007). These re-
analyses did not reveal any significant
associations (data not shown).
Our data do not support a strong
association of MC1R variants with BRAF
mutations in our North Carolina popula-
tion. Differences in the findings between
studies may be due, in part, to differing
frequencies of distinct MC1R variants
between study populations, which may
not all be similarly associated with BRAF
mutation. Another possibility is that the
risk-modifying effect of MC1R variants
may vary between populations based on
unidentified genetic factors. Climate dif-
ferences, such as ambient sun exposure,
could also influence the relationship
between MC1R status and BRAF-mutant
melanoma. However, despite our study
being the largest to date, the sample sizes
are relatively modest in all the studies,
and further investigation is necessary to
clarify the relationship of germlineMC1R
variants and BRAF-mutant melanomas
among different populations.
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TO THE EDITOR
The paired box transcription factor,
paired box 3 (PAX3), has an essential
role in embryonic melanocyte develop-
ment (Epstein, 2000). In mice, Pax3 is
expressed in the bulge region of adult
hair follicles, where melanocyte stem
cells are found (Nishimura et al., 2002;
Lang et al., 2005). Together with micro-
phthalmia transcription factor (MITF),
PAX3 regulates the balance betweenAbbreviation: PAX3, paired box 3
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committed melanoblast and terminal
differentiation (Lang et al., 2005). It is
generally thought that upon terminal
differentiation, the expression of PAX3
is reduced such that PAX3 is not
expressed in normal skin melanocytes
(Scholl et al., 2001; Lang et al., 2005),
and only sporadically in benign mela-
nocytic lesions (Plummer et al., 2008).
PAX3 expression in melanoma has been
interpreted as ‘‘re-expression’’, which is
suggested to contribute to uncontrolled
cell growth and loss of terminal differ-
entiation of melanocytes during tumor-
igenesis (Scholl et al., 2001; Blake and
Ziman, 2005; Plummer et al., 2008).
Our results using PAX3 immunohis-
tochemistry differed from that expected.
In comparing the expression of PAX3 in
adult human skin melanocytes, nevi,
and melanomas with the expression
of other melanogenesis factors, inclu-
ding microphthalmia transcription fac-
tor, Melan-A, and tyrosinase, medium to
strong nuclear PAX3 staining was ob-
served in the melanocytes of the epi-
dermal basal layer and in hair follicles
from adult skin tissues (12/12 cases),
which was similar to the expression of
microphthalmia transcription factor
(Figure 1a). PAX3 was also strongly
expressed in the outer root sheath
external layer melanocytes of hair folli-
cles (Figure 1a), which may represent
both hair follicle melanocyte stem cells
and amplifying progenitor cells.
Dual immunofluorescence staining
of PAX3 and tyrosinase, or PAX3 and
Melan-A revealed that PAX3-positive
cells in the epidermis were also positive
for tyrosinase (Figure 1d) and Melan-A
(Figure 1e). Hair follicles contained
both mature melanocytes that ex-
pressed PAX3 with tyrosinase and
Melan-A (see Supplementary Figure S1 on-
line), and melanoblasts that expressed
PAX3 without tyrosinase or Melan-A,
such as in the outer root sheath basal
layer and dermal papilla (Figure 1d and e,
Supplementary Figure S1 online).
These results suggested that PAX3 is
expressed in both melanoblasts and
differentiated melanocytes. Strong
PAX3 expression was also observed in
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Figure 1. Paired box 3 (PAX3) and microphthalmia-associated transcription factor (MITF) are expressed in normal adult human skin melanocytes and hair
follicles. (a, b) Immunohistochemistry shows PAX3- or MITF-positive melanocytes (arrows) within the epidermal basal layer and external root sheath, and/or the
cortex of hair follicle bulbs in the anagen or telogen phase (a) and sebaceous glands (b). (c–e) Dual immunofluorescent staining shows the co-expression of
(c) PAX3 (red) and MITF (green), (d) PAX3 (red) and tyrosinase (green), and (e) PAX3 (red) and Melan-A (green) in normal skin epidermis (c–e) and hair follicles
(d, e). DAPI, 40,6-diamidino-2-phenylindole; DP, dermal papilla; ES, epidermal surface; Tyro, tyrosinase. Bar¼50 mM.
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nevus melanocytes, either as single
melanocytes or as clusters of melano-
cytes appearing as nests of cells, which
could represent either acquired or con-
genital nevi (Figure 2 and Supplementary
Table S1 online). All 11 nevi examined
showed strong PAX3 expression.
PAX3 was expressed in primary
melanomas (31/33) as well as meta-
static melanomas (10/11) at various
levels (Figure 2, Supplementary Table
S1 online and summarized in Supple-
mentary Table S2 online). A compar-
ison of immunohistochemical and
clinical data failed to demonstrate a
relationship between the presence or
absence of PAX3, and melanoma sub-
type, the site of the primary, patient
age, patient sex, metastasis, growth
phase, Clark level, or Breslow thickness
(Supplementary Table S1 online).
Although previous reports have sug-
gested a lack of, or variable detection of
PAX3 in melanocytes of normal human
skin, nevi, and melanomas, or that the
expression of PAX3 tended to occur
more often in melanomas from younger
individuals (Scholl et al., 2001; Plum-
mer et al., 2008), we found no evidence
to support such variable detection of
PAX3 expression in skin melanocytes,
nevi, or in melanomas with respect to
patient age, melanoma stage, sun da-
mage, or solar elastosis. For instance,
we observed the expression of PAX3 in
relatively normal skin areas and in
scattered melanocytes within the tumor
in three cases of basal cell carcinoma,
all with signs of severe solar elastosis
(these three cases were not counted as
normal skin). We surmise that the
differences between our study and
previous studies could be technical;
we have used the same anti-Pax3 anti-
body as used previously (Plummer
et al., 2008). In our study, PAX3-
positive staining was always discern-
able from melanin because of a
clear color difference and cytoplasmic
localization of melanin (see Figure 2
legend; see Supplementary Figure S2
and Supplementary Methods online).
In our study, most of the PAX3-
positive cells in normal skin represented
differentiated melanocytes co-expressing
tyrosinase and Melan-A. A role for PAX3
in maintaining the undifferentiated phe-
notype of Schwann cells, neural crest
precursors, and lineage-committed mel-
anocytes has been suggested (Kioussi
et al., 1995; Lang et al., 2005; Wu et al.,
2008). PAX3 expression was thought to
switch off in fully differentiated cells, and
re-expression of PAX3 was suggested to
promote de-differentiation and contri-
bute to melanoma cell survival, thereby
promoting melanoma pathogenesis
(Scholl et al., 2001). However, our
observation of PAX3 expression in non-
malignant differentiated melanocytes
contradicts the notion that persistent
expression of PAX3 is pathogenic, and
50 μM
Figure 2. Expression of paired box 3 (PAX3) in nevi and melanomas. Immunohistochemical staining
of PAX3 in the (a) junctional nevus, (b) congenital nevus, (c) intradermal nevus, and (d) compound
nevus. Note, profound melanin was observed in the cytoplasm of epidermal keratinocytes of a junctional
nevus (a, arrows). Arrowheads indicate PAX3-positive melanocytes. Circles indicate nests of
melanocytes. Strong PAX3 staining in a multinucleated giant melanocyte of an intradermal nevus
(c, arrow). (e) Immunohistochemical staining of PAX3 in superficial spreading melanoma, (f) acral lentigo
malignant melanoma, (g) nodular melanoma, and (h) metastatic melanoma. Stronger staining of
PAX3 was observed in parts of the same tissue section as shown in the inset of (h). The use of
3,30diaminobenzidine enhancing solution rendered PAX3-positive staining different from the melanin
color, which was brown, whereas the former was dark gray. Aside from the color difference, nuclear
staining for PAX3 was always discernible from melanin in nevi melanocytes, or in melanoma cells
because melanin granules were located exclusively in the cytoplasm. Bar¼50 mM.
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suggests that further clarification of the
role of PAX3 expression in non-malig-
nant differentiated melanocytes is now
required. Extensive PAX3 expression in
benign and malignant tissues of the
melanocyte lineage, and absence of
expression in other types of skin cancer,
nevertheless suggests that PAX3 could be
used as an immunohistochemical marker
to differentially diagnose melanoma.
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TO THE EDITOR
Cathepsin S is a cysteine protease
linked to inflammatory processes, in-
cluding atherosclerosis and asthma.
The possibility that this or other
cysteine proteases might evoke itch or
be part of a classical ligand-receptor
signaling cascade has not been con-
sidered previously. We show here that
human cathepsin S evokes itch and
activates human protease-activated
receptors (PARs) 2 and 4.
The sensation of itch is mediated by
two distinct non-overlapping popula-
tions of cutaneous nerve fibers that
evoke comparable degrees of itch
(Johanek et al., 2008; Namer et al.,
2008). One set of fibers, the mechano-
insensitive population, is more respon-
sive to histamine than to cowhage. The
other set is mechanosensitive and is
more responsive to cowhage than to
histamine (Johanek et al., 2008; Namer
et al., 2008). Histamine is a classical
mediator of itch and is associated with
a wheal and flare. As most clinical
itches do not have a wheal or flare and
do not respond to antihistamines,
histamine is not thought to contribute
to most itches (Ikoma et al., 2006).
Cowhage refers to a tropical legume or,
in this case, the loose hairs that cover
the pods of Mucuna pruriens and evoke
itch. The active component of cowhage
is mucunain, a cysteine protease that
serves as a ligand for PARs 2 and 4
(Reddy et al., 2008). The identification
of an endogenous mediator with prop-
erties similar to cowhage could lead to
insights into non-histamine-mediated
itch. We focused on human cathepsin
S because it shares active site sequence
homology with mucunain and is selec-
tively up-regulated in human keratino-
cytes upon stimulation with interferon-
gamma, consistent with a possible
pruritic role in inflammatory skin dis-
ease (Schwarz et al., 2002).
There are 15 human cathepsins,
including 11 cysteine, 2 aspartic, and
2 serine proteases. Cathepsins were
traditionally considered lysosomal pro-
teases. It is now recognized that the
broad expression and range of pH
dependence of some cathepsins reveal
that they have many functional roles,
including tissue remodeling, metastasis
and inflammation. Examples of cysteine
cathepsin activities include cleavage of
collagen by cathepsin L to generate
endostatin (Felbor et al. 2000), an
endogenous inhibitor of angiogenesis,
and cleavage of the invariant chain in
antigen-presenting cells by cathepsin S
(Nakagawa et al., 1999) as part of the
inflammatory cascade.
There are four PARs and they are
members of the G-protein-coupled
receptor family. Their identified endo-
genous activators are all serine pro-
teases. These proteases trigger the
activation of PARs by unmasking
‘tethered ligand’ sequences near the
N-termini of the receptors. Certain
kallikrein-related peptidases and mastAbbreviation: PAR, protease-activated receptor
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